At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 540 target
Drug / intervention
anastrozole +2 moredrug
Likely dose
anastrozole 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Trial, Phase IIIb, Open Label Study of Exemestane After Two to Three Years of Anastrozole/Letrozole Treatment of Postmenopausal Women With Hormone Receptor Positive Breast Cancer
In Brief
A Phase 3 clinical trial evaluating anastrozole, letrozole, and 1 other intervention for Breast Cancer. Targeting 540 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the rate of disease free survival (DFS) and distant disease free survival (DDFS) at 5 years in postmenopausal women with hormone receptor and lymph node positive breast cancer randomized between anastrozole/letrozole 5 years and anastrozole/letrozole 2-3 years switching to exemestane 3-2 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
Collaborators--
Timeline
Phase 3UnknownOverdue
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedMay 2009
Primary CompletionJun 2010
Study CompletionJun 2011
TodayJul 2026
First PostedMay 15, 2009
Enrollment StartMar 1, 2008
Primary CompletionJun 1, 2010
Study CompletionJun 1, 2011
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 17.1 years ago
Interventions
anastrozoledrug
anastrozole 1 mg qd
letrozoledrug
letrozole 2.5 mg qd
exemestanedrug
exemestane 25 mg qd